当前位置：   首页 > 需求大厅

 >  生产研发 

 >  工艺技术 

本公司需要拉米夫定和齐多夫定的大生产工艺，有意向者请联系   [更多]

　　要求 　　1.不得侵犯他人专利，如有侵犯，提供者承担损失 　　2.要求有详细技术参数，不能只是一个合成路线 　　3.要求生产路线，成品率不得比现有公开合成方法低 　　4.要求为中试生产工艺   [更多]

我们需要设计自动崩解控制器用于靶向给药。自动崩解控制器，一旦触发，应该可以在温和条件(生理)下使药物分子的释放并激活。这个我们可以参考数量有限的文献中描述“self-immolative”（自动分解或自毁）连接器，但我们提出的自动崩解控制器不是这样的装置。具体链接为https://www.innocentive.com/ar/challenge/9933733，具体如下： Design of A Self-Cleaving Linker For Targeted Drug Delivery TAGS: Physical Sciences, Novel Molecules, Chemistry, Life Sciences, Theoretical-IP Transfer AWARD: $25,000 USD | DEADLINE: 4/27/15 | ACTIVE SOLVERS: 165 | POSTED: 3/26/15 The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of “self-immolative” linkers are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933733 Challenge Overview The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of such “self-immolative” linkers, based upon an elimination to generate a quinone methide, or utilizing a 5 or 6 member ring cyclization, are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property   [更多]

　　因公司发展需要，急需甲钴胺的大生产或中试后的生产工艺，要求能批量得到合格的产品，符合国家药品标准，步骤在两步之内，最好从VB12开始做，价格好商量，公司和个人合作都可!   [更多]

寻求常温结晶法生产高稳定性过碳酸钠 工业纯碱和双氧水加入内稳定剂，温度在15~30℃之间反应生成过碳酸钠。 目前工艺难度： (1)产品圆整度、硬度不好; (2)收率低; (3)稳定性差。急需解决。 预期达到技术、经济指标： 1、产品外观颗粒大小均匀、圆整度、硬度好。 2、稳定性等指标符合行业标准。 3、收率：碱0.72kg/kg产品，H2O2：1.2kg(27.5%)/kg产品。   [更多]

一、糠醛两步法生产工艺研究 糠醛是一种重要的化工原料，具有广阔的应用前景。目前，我公司生产糠醛主要采用一步法生产，一步法蒸汽消耗量大，一般吨醛消耗蒸汽18～25t，且该法糠醛收率最高只有6O%，原料得不到充分利用，并产生大量的废渣。随着糠醛工业的发展，以及原料综合利用要求的提高，发展两步法糠醛生产工艺，分离原料中的纤维素和半纤维素并分别加以利用，是糠醛工业的必然发展趋势，但是两步法工艺较为复杂，设备投资高，第二步脱水工艺条件不十分成熟， 因此公司希望可以与其他单位合作，共同研究糠醛两步法生产工艺，以达到提高收率，抑制生成的糠醛发生副反应，并提高原料综合利用率。 二、糠醛生产中纤维素的深度开发 1、生物基材料---糠醛生产中纤维素的深度开发; 2、二氧化硫脲漂白高岭土的应用技术; 3、二氧化硫脲在靛蓝印染上的应用 三、糠醛渣制造生物柴油深度开发研究 我公司水解釜排出来的废渣，经过锅炉烟道气流化干燥后直接进入锅炉去燃烧。锅炉燃烧所产生的烟道气经旋风除尘，湿法脱硫，硫化干燥水解废渣，最后再进入高空烟囱排放。但是由于糠醛渣含水率高，发热值低，燃烧处理时利用率较低。因此，糠醛渣深度开发、有效利用成为糠醛生产企业的一大难题。 由于生物柴油具有优良的环保特性，良好的燃料性能，并具有可再生性，开发糠醛渣制造生物柴油新技术，解决企业糠醛渣废固利用，增加效益，提升企业技术水平和经济效益。 因此公司希望可以与其他单位合作，共同研发布   [更多]

合理的大生产工艺即可或中试工艺   [更多]

标题：求 维生素D滴剂或维生素D2软胶囊一致性评价 详细要求： 需求名称：维生素D滴剂或维生素D2软胶囊一致性评价专家 具体要求：寻找一个维生素D滴剂或维生素D2软胶囊一致性评价方面的专家或团队，要求擅长一致性评价相关工作和法规，有维生素D的研究背景，能够满足一致性评价方面的要求，有一致性评价成功案例的优先。 交稿方式：直接点击交稿在线交稿就是了，我会每天过来看的，谢谢各位   [更多]

一、2，2-双二苯基膦-1，1-联萘的制备技术 技术难题：2，2-双二苯基膦-1，1-联萘的制备技术。解决技术难题要求达到的技术目标：纯度大于98%，外观为白色固体，总收率大于60%。   [更多]

这是高速度的药物API的片剂压制的一个主要问题。活性药物成分在压冲过程中的冲头被粘住而使片剂重量和剂量有所损失产生不同。我们寻找一种计算片剂压片机高速冲头上剂量和重量损失的模型，用以改进片剂工艺。具体请看下面英文描述：https://www.innocentive.com/ar/challenge/9933670 AWARD: $10,000 USD | DEADLINE: 2/22/15 | ACTIVE SOLVERS: 9 | POSTED: 1/23/15 Solid dosage forms (e.g. tablets) are the preferred dosage unit for pharmaceutical products. These units are produced by compressing particulate formulations. A major problem in the high speed pressing of tablet formulations of pharmaceutical API’s (Active Pharmaceutical Ingredient) is they sometimes tend to stick to the punches during the compression process. This causes weight loss defects in the tablets and thus costly manufacturing defects during production. A model is required to predict sticking of formulations in high speed presses to prevent losses in production. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933670 Challenge Overview Tablets are the main dosage form of choice for medicines. They have manufactured by compressing formulations which may consist of blended powders or granules. A major problem in the high speed pressing of tablet formulations of new medicines is they sometimes tend to stick to the surfaces of compaction equipment. This causes tablet weight and hence dose reduction and thus costly manufacturing defects during production. The phenomenon is frequently only observed on scale up due to the lengthy run times at large scale and is difficult to reproduce at smaller scales. New models (or partial model concepts) are required to improve the overall modeling of “stickiness” in tablet compression and predict the extent beforehand. Suggestions for improvements to either process route or equipment or to formulation ingredients to prevent sticking from the models are also desired. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be   [更多]